Bristol Myers Squibb stock gains on a new FDA approval
Published on 08/19/2026 at 16:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Bristol Myers Squibb (US0897961004) stock gained another catalyst after the FDA approved Zenbexus on August 13, 2026, while the shares closed at $66.07 on August 18, 2026. The company also reported second-quarter 2026 revenue of $12.97 billion and EPS of $2.04, both key markers for how the market is reading the name now.
Approval adds a fresh product hook
According to ad hoc news on the Zenbexus approval, the FDA cleared the drug for multiple myeloma in combination with daratumumab and dexamethasone for adults who have already had at least one prior line of therapy. That gives the stock a commercial catalyst tied to a named medicine, not just to the earnings report.
The same report put the market cap at $132.18 billion and the after-hours quote at $66.15 on August 18, 2026. It also noted that the stock was up 2.23% to $66.07 in the latest trading snapshot, which keeps the move grounded in a concrete session rather than a vague reaction.
Quarterly numbers still matter
The latest quarter showed revenue of $12.97 billion versus $11.74 billion expected, a beat of $1.23 billion. EPS came in at $2.04 versus $1.60 expected, a difference of $0.44, while revenue rose 5.7% from the year-earlier quarter.
That comparison matters because the approval lands on top of a report already marked by a clear earnings surprise. In the same period last year, the company earned $1.46 per share, which frames the current quarter as a much stronger operating base.
Guidance and valuation
MarketBeat's filing coverage said Bristol Myers Squibb set FY 2026 EPS guidance at $6.75 to $7.00. On the same page, the market cap was listed at $134.97 billion, the P/E ratio at 14.55, and the beta at 0.22, which leaves the stock in large-cap pharma territory with a relatively low market multiple.
The market also has a simple comparison point: the current consensus target was listed at $66.06 while the stock closed at $66.07 on August 18, 2026. That puts the shares almost exactly in line with the average target cited in the current market snapshot.
Zenbexus in context
Zenbexus, also known as iberdomide, now sits beside daratumumab and dexamethasone in the company's multiple myeloma portfolio. For investors, the key point is that the approval adds another marketed oncology asset to a company that already reported $12.97 billion in quarterly revenue.
Shares closed at $66.07 on August 18, 2026, with extended trading showing $66.15 that night. The stock's 52-week range in the same market snapshot ran from $42.52 to $68.10, leaving it below the high but well above the low.
Investor Relations
Company: Bristol Myers Squibb Company
ISIN: US0897961004
Ticker: BMY
Exchange: NYSE
Price (as of August 18, 2026, 4:00 p.m. ET): $66.07 USD
Market cap: $132.18 billion (as of August 18, 2026)
Sector / Industry: Health Care / Biotechnology
Index membership: S&P 500
Next earnings date: October 29, 2026
More on Bristol Myers Squibb stock
The company's oncology portfolio includes Zenbexus, and the new approval adds a second commercial story to the current earnings backdrop.
